5/10/2013

Trevena and Forest Laboratories entered into a licensing-option deal involving TRV027, Trevena's drug candidate for acute heart failure. Forest agreed to make a $30 million equity stake in Trevena in exchange for an option to license TRV027. If Forest exercises its option, Trevena will be entitled to as much as $430 million in milestone fees plus sales royalties.

Related Summaries